Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Pharmaceuticals Group Qingdao Guofeng Pharmaceutical, obtained a drug registration certificate from China's National Medical Products Administration for the Wenjing decoction granules, according to a Thursday filing with the Shanghai Stock Exchange.
The Chinese traditional medicine is used for various purposes, such as relieving pain and balancing blood circulation for women with irregular menstruation and lower abdominal pain.
The pharmaceutical company invested 4.7 million yuan in the drug's research and development, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.